Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>KN-93 Phosphate

KN-93 Phosphate Sale

目录号 : GC12804

A CaMKII inhibitor

KN-93 Phosphate Chemical Structure

Cas No.:1188890-41-6

规格 价格 库存 购买数量
10mM (in 1mL DMSO) 待询 待询
1mg
¥450.00
现货
5mg
¥900.00
现货
10mg
¥1,125.00
现货
25mg 待询 待询

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1]:

Cell lines

Human hepatic stellate cell line LX-2

Preparation method

Soluble in DMSO >30mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

5, 10, 25, 50μmol/L for 24h; 10 μmol/L for 4, 8, 16, 24, 48h

Applications

KN-93 decreased the proliferation of human hepatic stellate cells in a dose dependent manner after 24 h treatment. Incubation of 10 μmol/L KN-93 induced the cell growth reduction in a time-dependent manner. KN-93 reduced the expression of p53 and p21.

Animal experiment [2]:

Animal models

adult Sprague Dawley female rats (model of PD was induced by 6-hydroxydopamine (OHDA))

Dosage form

1μg, 2μg, or 5μg KN-93, intrastriatal injections

Application

The data indicated that intrastriatal injections of KN-93 were beneficial in reducing the expression of LID (levodopa-induced dyskinesia) by lowering the expression of pGluR1S845(Phosphorylated GluR1(Glutamate receptor 1) at Serine-845) via suppressing the activation of CaMKII (calcium -dependent protein kinase II) in PD rats. Decreased expression of pGluR1S845 further reduced the expression of Gad1(glutamate decarboxylase 1) and nr4a1(nuclear receptor subfamily 4, group A, member 1) in PD rats.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. An P, Zhu JY, et al, KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8.

[2]. Yang X, Wu N, et al, Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat. 2013;9:1213-20. doi: 10.2147/NDT.S45422.

产品描述

KN-93 phosphate is the water soluble form of KN-93. It is a potent, selective and cell permeable inhibitor of CaM kinase II (IC50= 0.37 μm, Ki=370 nm) [1]
CaMK II (calcium/calmodulin-dependent protein kinase II) is a multifunctional serine/threonine kinase with various roles in different physiological systems.
Since CaMK II can enhance cell proliferation, the CaMK II inhibitor KN-93 blocked the cell proliferation by regulating the expression of p53 and p21 in human hepatic stellate cells. [2] KN-93 inhibited the autophosphorylation of both α and β subunits of CaMK II. Moreover, KN-93 reduced dopamine level via modulating the TH reaction rate to reduce the Ca2+-mediated phosphorylation levels of the TH molecule in PC12h cells.[1] As CaMK II is necessary for cell cycle progression through G1, KN-93 also induced G1 cell cycle arrest and apoptosis in NIH 3T3 cells.[3]
In MRL/lpr Foxp3-GFP mice, KN-93 promoted the generation of Foxp3 regulatory T cells through the inhibition of CaMK IV in the spleen, peripheral lymph nodes and peripheral blood with decreased skin and kidney damage. [4] In a rat model of Parkinson's disease, intrastriatal injection of KN-93 relieved the levodopa-induced dyskinesia by suppressing the CaMK II activation. [5]
References:
[1] Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H. The newly synthesized selective Ca2+/calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. Biochem Biophys Res Commun. 1991 Dec 31;181(3):968-75.
[2] An P, Zhu JY, Yang Y, Lv P, Tian YH, Chen MK, Luo HS. KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. World J Gastroenterol. 2007 Mar 7;13(9):1445-8.
[3] Tombes RM, Grant S, Westin EH, Krystal G. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK-II (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995 Sep;6(9):1063-70.
[4] Koga T, Mizui M, Yoshida N, Otomo K, Lieberman LA, Crispín JC, Tsokos GC.KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺ regulatory T cells in MRL/lpr mice. Autoimmunity. 2014 Nov;47(7):445-50.
[5] Yang X, Wu N, Song L, Liu Z. Intrastriatal injections of KN-93 ameliorates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Neuropsychiatr Dis Treat. 2013;9:1213-20. doi: 10.2147/NDT.S45422.

Chemical Properties

Cas No. 1188890-41-6 SDF
Canonical SMILES CN(C/C=C/C1=CC=C(Cl)C=C1)CC2=CC=CC=C2N(CCO)S(C3=CC=C(OC)C=C3)(=O)=O.O=P(OO)=O.[HH]
分子式 C26H32ClN2O8PS 分子量 599.03
溶解度 ≥ 29.95mg/mL in DMSO 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.6694 mL 8.3468 mL 16.6937 mL
5 mM 0.3339 mL 1.6694 mL 3.3387 mL
10 mM 0.1669 mL 0.8347 mL 1.6694 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置